Biomarin Pharmaceutical
CA · 11 filings, 2025
What the money shows
Biomarin Pharmaceutical reported $1.3M in federal lobbying for 2025 across 11 filings. The filings name 3 lobbying firms, led by LMH Strategic Solutions and BGR Government Affairs. The filing text lists 6 issue areas.
Sources: Senate LDA · FEC
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). via Wikipedia ↗
1Lobbies on
Its filings list: Medicare/Medicaid · Health Issues · Pharmacy · Tariff (miscellaneous tariff bills) · Taxation/Internal Revenue Code · Budget/Appropriations
2Through these firms · 3
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5236A bill to amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services…
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5227A bill to amend the Internal Revenue Code of 1986 to allow certain distributions from long-term qualified t…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…